首页> 美国卫生研究院文献>Regenerative Therapy >A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells
【2h】

A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells

机译:确保自体人类诱导的多能干细胞样细胞加工产生的药品和医疗器械的质量和安全性的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human iPS cells or iPS cell-like cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-4, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Induced Pluripotent Stem(-Like) Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from autologous human iPS cells (or iPS cell-like cells), in addition to similar points to consider that are described previously for autologous human stem cell-based products. Major additional points include (1) possible existence of autologous human iPS cell-like cells that are different from iPS cells in terms of specific biological features; (2) the use of autologous human iPS(-like) cells as appropriate starting materials for regenerative medicine, where necessary and significant; (3) establishment of autologous human iPS(-like) cell lines and their characterization; (4) cell banking and/or possible establishment of intermediate cell lines derived from autologous human iPS(-like) cells at appropriate stage(s) of a manufacturing process, if necessary; and (5) concerns about the presence of undifferentiated cells in the final product; such cells may cause ectopic tissue formation and/or tumorigenesis. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities.
机译:为了建立一系列合理的措施,以使用人类干细胞为基础的产品来促进再生医学的健康发展,我们研究了科学原理,概念和基本技术要素,以确保自体人类iPS细胞衍生的治疗产品的质量和安全性。或iPS类细胞,并考虑到人类干细胞衍生产品的科学技术进步,道德规范,管理原则和国际趋势。这就导致了日本官方公告号0907-4的制定,即“确保自处理人类诱导型多能干细胞(类)细胞衍生的药品和医疗器械的质量和安全性指南”,日本厚生劳动省食品安全局,2012年9月7日。除了考虑类似的观点外,本文还探讨了自体人类iPS细胞(或iPS细胞样细胞)衍生产品的各个方面。先前针对自体人类干细胞产品进行了描述。其他主要要点包括:(1)自体人类iPS细胞样细胞的可能存在,这些细胞在特异性生物学特征方面不同于iPS细胞; (2)在必要且重要的情况下,使用自体人类iPS(样)细胞作为再生医学的适当起始材料; (3)建立自体人类iPS(样)细胞系并对其特性进行鉴定; (4)必要时在制造过程的适当阶段进行细胞库和/或可能建立自体人类iPS样细胞衍生的中间细胞系; (5)对终产物中未分化细胞的存在的担忧;此类细胞可能引起异位组织形成和/或肿瘤发生。该指南的最终目标是尽快为患有传统疾病难以治疗的严重疾病患者提供合适的医疗机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号